Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Mudcat who wrote (28443)	3/2/1999 9:34:00 AM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

Targretin is a Rexinoid as are LGD1268, LGD1324, and other LGND and AGN second generation compounds. ERA-327, TSE424, Droloxifene, CP-366,156, Idoxifene, Evista, Tamoxifen are SERMs Rexinoids compete with Rexinoids SERMs compete with SERMs SERMs and Rexinoids don't compete, they synergize ERA-937 competes with the SERMs above, not Targretin or othe Rexinoids Combinations will be Rexinoids combining with SERMs, not SERMs with SERMs or Rexinoids with Rexinoids LGND's current Phase II trial with Targretin combines a SERM (Tamoxifen) with a Rexinoid (Targretin). Other LGND Breast Cancer trails also combine a Rexinoid (Panretin), with a SERM (Tamoxifen). I know of no Rexinoid/Rexinoid or SERM/SERM combination trials. You misunderstanding is at a VERY basic level. Do you know of any SERM/SERM combos or Rexinoid/Rexinoid combos?